S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:FGEN

FibroGen (FGEN) Stock Forecast, Price & News

$16.98
-0.80 (-4.50%)
(As of 04:18 PM ET)
Compare
Today's Range
$15.61
$17.73
50-Day Range
$16.11
$20.59
52-Week Range
$8.67
$25.69
Volume
1.78 million shs
Average Volume
953,210 shs
Market Capitalization
$1.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.83

FibroGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
50.5% Upside
$24.83 Price Target
Short Interest
Bearish
6.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
-0.09mentions of FibroGen in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$1.47 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.83) to ($2.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

369th out of 986 stocks

Pharmaceutical Preparations Industry

167th out of 480 stocks


FGEN stock logo

About FibroGen (NASDAQ:FGEN) Stock

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Stock News Headlines

Check Out What Whales Are Doing With FGEN
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Stifel Upgrades FibroGen (FGEN)
FibroGen Unusual Options Activity
FibroGen Slips on Test Results
Analysts Set FibroGen, Inc. (NASDAQ:FGEN) PT at $23.40
See More Headlines

FGEN Price History

FGEN Company Calendar

Last Earnings
5/08/2023
Today
6/09/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FGEN
Employees
566
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.83
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+47.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-293,650,000.00
Net Margins
-264.63%
Pretax Margin
-266.12%

Debt

Sales & Book Value

Annual Sales
$140.73 million
Book Value
($0.02) per share

Miscellaneous

Free Float
94,830,000
Market Cap
$1.64 billion
Optionable
Optionable
Beta
0.78

Key Executives

  • Enrique A. Conterno
    Chief Executive Officer & Director
  • Juan Graham
    Chief Financial Officer & Senior Vice President
  • Elias Kouchakji
    Senior VP-Clinical Development & Drug Safety
  • Mark Eisner
    Chief Medical Officer & Executive Vice President
  • John Hunter
    Chief Scientific Officer













FGEN Stock - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FGEN shares.
View FGEN analyst ratings
or view top-rated stocks.

What is FibroGen's stock price forecast for 2023?

6 brokerages have issued 12 month price targets for FibroGen's stock. Their FGEN share price forecasts range from $14.00 to $35.00. On average, they predict the company's share price to reach $24.83 in the next year. This suggests a possible upside of 47.8% from the stock's current price.
View analysts price targets for FGEN
or view top-rated stocks among Wall Street analysts.

How have FGEN shares performed in 2023?

FibroGen's stock was trading at $16.02 on January 1st, 2023. Since then, FGEN shares have increased by 4.9% and is now trading at $16.80.
View the best growth stocks for 2023 here
.

Are investors shorting FibroGen?

FibroGen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,690,000 shares, an increase of 16.8% from the April 30th total of 4,870,000 shares. Based on an average daily volume of 910,800 shares, the days-to-cover ratio is presently 6.2 days. Approximately 6.4% of the shares of the company are short sold.
View FibroGen's Short Interest
.

When is FibroGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our FGEN earnings forecast
.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) released its quarterly earnings results on Monday, May, 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.05. The biopharmaceutical company had revenue of $36.16 million for the quarter, compared to the consensus estimate of $31.52 million. FibroGen had a negative trailing twelve-month return on equity of 879.75% and a negative net margin of 264.63%. FibroGen's revenue was down 40.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.68) earnings per share.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.56%), State Street Corp (4.18%), First Trust Advisors LP (2.79%), Baker BROS. Advisors LP (2.70%), Armistice Capital LLC (2.37%) and Geode Capital Management LLC (1.77%). Insiders that own company stock include Christine Chung, Enrique A Conterno, Juan Graham, K Peony Yu, Kalevi Kurkijarvi, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends
.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $16.80.

How much money does FibroGen make?

FibroGen (NASDAQ:FGEN) has a market capitalization of $1.64 billion and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis.

How many employees does FibroGen have?

The company employs 566 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.

This page (NASDAQ:FGEN) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -